Is levetiracetam teratogenic, and can it be safely used during pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Levetiracetam Teratogenicity

Levetiracetam is considered one of the safest antiseizure medications for use during pregnancy, with a low risk of major congenital malformations comparable to baseline population risk (1-3%), and is recommended as first-line monotherapy for women with epilepsy of childbearing potential. 1

Safety Profile in Pregnancy

The most recent 2026 guidelines from Epilepsia explicitly recommend levetiracetam (along with lamotrigine) as first-line monotherapy for women with epilepsy of childbearing potential with either focal or generalized seizures when pregnancy cannot be excluded. 1 This recommendation is based on:

  • Major malformation rates: Multiple studies demonstrate levetiracetam monotherapy carries a malformation risk of approximately 0.7-2.2%, which falls within the baseline population risk of 1-3% 2, 3
  • No adverse neurodevelopmental outcomes: Unlike valproate and topiramate, adverse neurodevelopmental outcomes have not been demonstrated for levetiracetam 1
  • Declining malformation rates: The shift toward prescribing lower-risk ASMs like levetiracetam and lamotrigine has contributed to declining malformation rates over recent years 1

Neurodevelopmental Outcomes

Levetiracetam does not appear to impair cognitive development or cause behavioral problems in exposed children. 4 Available data show:

  • Comparable outcomes versus unexposed controls
  • Favorable outcomes versus valproate on global and specific cognitive abilities
  • No significant dose-effect association for neurodevelopmental outcomes
  • Follow-up data available, though not as extensive as for lamotrigine

Important Caveats and Monitoring

Pharmacokinetic Changes

Levetiracetam serum concentrations decline substantially during pregnancy to approximately 54% of baseline due to increased clearance 1. This requires:

  • Regular therapeutic drug monitoring (TDM) throughout pregnancy - recommended monthly in clinical practice 1
  • Using preconception levels as reference
  • Anticipatory dose adjustments when levels drop below 65% of baseline (associated with breakthrough seizures) 1
  • Prompt postpartum dose reduction as drug clearance normalizes rapidly after delivery 1

Polytherapy Concerns

A critical caveat: While levetiracetam monotherapy is safe, polytherapy outcomes vary significantly by combination 1:

  • Levetiracetam + lamotrigine: One study found an unexpectedly high risk of spontaneous abortion (adjusted HR 3.01) and a non-significant increase in major birth defects (7.7%) 5, though adverse neurodevelopmental outcomes have not been demonstrated for this combination 1
  • Levetiracetam + valproate: Higher malformation rates (6.9%) 2
  • Levetiracetam + carbamazepine: Higher malformation rates (9.4%) 2

The previously observed increased risk with polytherapy appears largely attributable to valproate-containing regimens rather than the number of medications per se 1

Additional Considerations

  • Lower birth weight in male neonates has been reported with levetiracetam monotherapy compared to lamotrigine, requiring further investigation 5
  • Folic acid supplementation (1-2 mg/day) is recommended starting at least 4 weeks before conception 1
  • Breastfeeding is encouraged - levetiracetam is excreted in breast milk but infant exposure is substantially lower than in utero exposure 1

Comparison to Other ASMs

The FDA label classifies levetiracetam as Pregnancy Category C, noting developmental toxicity in animal studies at doses similar to or greater than human therapeutic doses 6. However, this classification is outdated compared to current clinical evidence.

In contrast to levetiracetam, the following ASMs are NOT recommended:

  • Valproate: Dose-dependent association with major malformations and intellectual disability 1
  • Topiramate: Linked to autism spectrum disorder and intellectual disability 1
  • Carbamazepine, phenobarbital, phenytoin: Not recommended 1

Oxcarbazepine is advised as an alternative for focal epilepsy when levetiracetam or lamotrigine are unsuitable 1

Clinical Algorithm

  1. Preconception: Switch to levetiracetam or lamotrigine if not already on these agents; establish baseline serum levels; start folic acid 1-2 mg/day
  2. During pregnancy: Monthly TDM; adjust doses to maintain preconception levels; avoid drops below 65% of baseline
  3. Postpartum: Rapid dose reduction guided by prepregnancy target dose and clinical symptoms
  4. Avoid abrupt discontinuation at any point due to seizure recurrence risk 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.